Drug discovery for hearing loss: Phenotypic screening of chemical compounds on primary cultures of the spiral ganglion


    loading  Checking for direct PDF access through Ovid

Abstract

In the United States there are, at present, no drugs that are specifically FDA approved to treat hearing loss. Although several clinical trials are ongoing, including one testing D-methionine that is supported by the US Army, none of these trials directly address the effect of noise exposure on cochlear spiral ganglion neurons. We recently published the first report of a systematic chemical compound screen using primary, mammalian spiral ganglion cultures in which we were able to detect a compound and others in its class that increased neurite elongation, a critical step in restoring cochlear synapses after noise induced hearing loss. Here we discuss the issues, both pro and con, that influenced the development of our approach. These considerations may be useful for future compound screens that target the same or other attributes of cochlear spiral ganglion neurons.HighlightsScreening small compounds on deaf animal models is prohibitive in time and resources.Primary cultures of cochlear neurons can be used for small molecule screening.Assay, stimulus and readout relevance, validation and reproducibility are key.Narrowing down a chemical library to a few compounds allows validation in vivo.

    loading  Loading Related Articles